Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8661712 | International Journal of Cardiology | 2018 | 7 Pages |
Abstract
Among patients with NVAF in routine clinical practice, there were no statistically significant differences in risk of stroke or systemic embolism or major bleeding in propensity-matched comparisons between apixaban, dabigatran, and rivaroxaban used in standard doses. While analyses indicate that more than moderate differences can be excluded, smaller differences cannot be ruled out.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Niklas W. Andersson, Henrik Svanström, Marie Lund, Björn Pasternak, Mads Melbye,